Expanding First-line Options for Depression and Matching Treatments to Patients: Hatha Yoga vs. Behavioral Therapy

Sponsor
Massachusetts General Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05546697
Collaborator
Butler Hospital (Other), Hennepin Healthcare Research Institute (Other), Medical University of South Carolina (Other), Brown University (Other), Wake Forest University Health Sciences (Other)
518
1
2
40
13

Study Details

Study Description

Brief Summary

This is a parallel group study design. The investigators propose to compare an online, synchronous group-based yoga intervention developed for individuals with depression to an online, synchronous individualized, evidence-based behavioral therapy for depression, or Brief Behavioral Activation Treatment for Depression (BA). This study is a multi-site randomized trial of adults with clinically significant depressive symptoms. Participants (N=518) will be randomized in an equal allocation ratio (i.e., 1:1) across two intervention groups: yoga and BA. Interventions will be provided over a 12-week period and assessments will occur at baseline (week 0), week 6, week 12, week 18, and week 24.

Condition or Disease Intervention/Treatment Phase
  • Other: Online- Yoga-based Intervetion
  • Behavioral: Online- BA
N/A

Detailed Description

The first goal of the proposed research is to determine whether a hatha yoga program for depression is non-inferior to BA in reducing depressive symptoms over a 6-month period.

Our second goal is to identify individual-level characteristics that predict heterogeneity of treatment effect (HTE) to develop guidance for matching patients to the optimal depression treatment.

Sample- Our sample will be representative of the target population: individuals with depression. There are several aspects of the current study design that the investigators believe will enhance recruitment in diverse patient populations.

  • Both study interventions will be offered via telehealth to reduce barriers to access (e.g., childcare, time, parking/transportation costs, less time out of work).

  • The investigators have study funds to cover the costs of the technology for people who do not have a device or home-based internet access. Further, to decrease barriers related to digital literacy, study staff will be proactive about assisting participants with setting up technology, using technology and troubleshooting if needed.

  • The investigators have study funds to pay for the BA therapists for participants who are uninsured.

  • The investigators have study funds to offer the yoga intervention free of charge to participants.

  • The investigators will offer study participation to Spanish-speakers.

  • The investigators have an Advisory Board of stakeholders with diverse backgrounds (i.e., racially and ethnically diverse as well as diversity in socioeconomic status, educational background, and clinical features) to assist with the implementation and oversight of this study.

Participants will be paid for completing study assessments, they will not be compensated for attending study intervention sessions.

Assessments occur at Baseline (week 0, prior to randomization), and weeks 6, 12, 18, and 24. All self-report assessments will be available in English or Spanish. When an assessment is due, participants will be sent an automated link to complete the assessments via REDCap. In addition, they will receive reminders if they do not complete the assessment, and, if needed, follow-up phone calls from study staff. It is expected that the assessments at Weeks 0 (baseline) and 24 (end of treatment) will take approximately 45 min to complete, at Week 12 will take approximately 30 min to complete and at Weeks 6 and 18 will take approximately 20 min to complete.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
518 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
COMPARE: Expanding First-line Options for Depression and Matching Treatments to Patients: Hatha Yoga vs. Behavioral Therapy
Anticipated Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
May 1, 2026
Anticipated Study Completion Date :
May 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Yoga-based Intervention

Yoga classes will be gentle and physically accessible for people who are naïve to yoga. Teachers will frequently guide participants to focus on their breathing and coordinate movements with breath. Teachers will offer variations on the postures and encourage participants to choose variations that provide some challenge but do not cause strain or pain. Classes will be 1 hour long and include a brief sitting meditation, warm-ups, standing postures, and a final resting meditation. All participants will be invited to attend a synchronous yoga class via a HIPAA-compliant videoconference option once per week during the first 3 months of the study. Classes will be offered at multiple times throughout the week.

Other: Online- Yoga-based Intervetion
See arms description

Active Comparator: Behavioral Activation

The goal of Behavioral Activation Psychotherapy is to help people identify and (re)engage in meaningful and positive activities through psychoeducation, identification of values and associated activities, goal setting, problem-solving, and monitoring of goal completion. There will be a BA manual for therapists and training provided by study staff on the manual (e.g., asynchronous and synchronous training sessions). BA therapists will be community clinicians. BA will be provided individually via telehealth and will be billed to participant insurance. At the start of BA treatment, participants will be oriented to the time-limited nature of BA, with the expectation that they will attend 8 sessions over the course of 3 months.

Behavioral: Online- BA
See arms description

Outcome Measures

Primary Outcome Measures

  1. Patient Health Questionnaire-9 (PHQ-9) [Week: 0]

    It is a 9-item self-report questionnaire that is widely used to assess depression symptom severity. A PHQ-9 score ≥10 has a sensitivity of 88% and a specificity of 88% for major depression. PHQ-9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively.

  2. Patient Health Questionnaire-9 (PHQ-9) [Week: 6]

    It is a 9-item self-report questionnaire that is widely used to assess depression symptom severity. A PHQ-9 score ≥10 has a sensitivity of 88% and a specificity of 88% for major depression. PHQ-9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively.

  3. Patient Health Questionnaire-9 (PHQ-9) [Week:12]

    It is a 9-item self-report questionnaire that is widely used to assess depression symptom severity. A PHQ-9 score ≥10 has a sensitivity of 88% and a specificity of 88% for major depression. PHQ-9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively.

  4. Patient Health Questionnaire-9 (PHQ-9) [Week:18]

    It is a 9-item self-report questionnaire that is widely used to assess depression symptom severity. A PHQ-9 score ≥10 has a sensitivity of 88% and a specificity of 88% for major depression. PHQ-9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively.

  5. Patient Health Questionnaire-9 (PHQ-9) [Week: 24]

    It is a 9-item self-report questionnaire that is widely used to assess depression symptom severity. A PHQ-9 score ≥10 has a sensitivity of 88% and a specificity of 88% for major depression. PHQ-9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively.

Secondary Outcome Measures

  1. World Health Organization-5 Well-Being Index (WHO-5) [Week: 0, 6, 12, 18, 24]

    It is a 5-item self-report questionnaire with positively-worded statements related to positive mood, vitality, and general interest over the prior two weeks. The WHO-5 is reliable, has shown strong construct validity as a measure of general quality of life, and is sensitive to change.

  2. PROMIS-29 [Week: 0, 6, 12, 18, 24]

    It has seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, social functioning, sleep disturbance) using four items per domain. It has demonstrated good psychometric properties.

Other Outcome Measures

  1. PROMIS Anger [Week: 0, 6, 12, 18, 24]

    It is a 5-item self-report scale that the investigators will use this to assess the exploratory outcome of irritability.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Aged 18 years old or older

  2. Depressive symptoms at study entry (PHQ-9≥10)

  3. Provides informed consent

  4. Able to read and understand English or Spanish.

  5. Live in NC, MA, MN, or RI

Exclusion Criteria:
  1. PHQ-9 > 20

  2. A bone fracture or joint surgery in the past 6 months

  3. Unable to walk

  4. Severe heart failure or lung disease

  5. Had a healthcare provider tell them it is unsafe to exercise

  6. Currently pregnant

  7. Are already engaged in study interventions (i.e., engaged in yoga practice or psychotherapy more than once in the past 4 weeks).

  8. Have active suicidal thinking (i.e., PHQ-9 item 9 ≥1 and a positive response to CSSR-S screener items 2, 3, 4, 5, or 6)

  9. Are currently experiencing manic symptoms (Altman Self-Rating Mania Scale score ≥ 6).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Massachusetts General Hospital Boston Massachusetts United States 02114

Sponsors and Collaborators

  • Massachusetts General Hospital
  • Butler Hospital
  • Hennepin Healthcare Research Institute
  • Medical University of South Carolina
  • Brown University
  • Wake Forest University Health Sciences

Investigators

  • Principal Investigator: Louisa Sylvia, PhD, Massachusetts General Hospital
  • Principal Investigator: Lisa Uebelacker, PhD, Butler Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Louisa Grandin Sylvia, Associate Director, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT05546697
Other Study ID Numbers:
  • 2022P001701
First Posted:
Sep 21, 2022
Last Update Posted:
Sep 21, 2022
Last Verified:
Sep 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Louisa Grandin Sylvia, Associate Director, Massachusetts General Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 21, 2022